{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,4,24]],"date-time":"2024-04-24T00:37:14Z","timestamp":1713919034696},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,23]]},"DOI":"10.7759\/cureus.58812","type":"journal-article","created":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T11:29:56Z","timestamp":1713871796000},"source":"Crossref","is-referenced-by-count":0,"title":["A Breath of Relief: Oxymetazoline and Flunisolide Nasal Spray in the Management of Myasthenia Gravis Ptosis"],"prefix":"10.7759","author":[{"given":"Toni","family":"Aloyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Najla","family":"Shilleh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjun","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barsam","family":"Barsamian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Sovory","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/OPX.0000000000001800","article-title":"Case report: treatment of myasthenic ptosis with topical ocular oxymetazoline","volume":"98","author":"Cooper J","year":"2021","unstructured":"Cooper J, Yang D. Case report: treatment of myasthenic ptosis with topical ocular oxymetazoline. Optom Vis Sci. 2021, 98:1317-20. 10.1097\/OPX.0000000000001800","journal-title":"Optom Vis Sci"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.36351","article-title":"Oxymetazoline hydrochloride eye-drops as treatment for myasthenia gravis-related ptosis: a description of two cases","volume":"15","author":"Taha M","year":"2023","unstructured":"Taha M, Li Y, Morren J. Oxymetazoline hydrochloride eye-drops as treatment for myasthenia gravis-related ptosis: a description of two cases. Cureus. 2023, 15:e36351. 10.7759\/cureus.36351","journal-title":"Cureus"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27851","article-title":"Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: a pilot clinical trial","volume":"68","author":"Agha M","year":"2023","unstructured":"Agha M, Ismail H, Sawaya R, Salameh J. Efficacy of apraclonidine eye drops in treating ptosis secondary to myasthenia gravis: a pilot clinical trial. Muscle Nerve. 2023, 68:206-10. 10.1002\/mus.27851","journal-title":"Muscle Nerve"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus NE","year":"2019","unstructured":"Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJ. Myasthenia gravis. Nat Rev Dis Primers. 2019, 5:30. 10.1038\/s41572-019-0079-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51317.x","article-title":"The course of myasthenia gravis and therapies affecting outcome","volume":"505","author":"Grob D","year":"1987","unstructured":"Grob D, Arsura EL, Brunner NG, Namba T. The course of myasthenia gravis and therapies affecting outcome. Ann N Y Acad Sci. 1987, 505:472-99. 10.1111\/j.1749-6632.1987.tb51317.x","journal-title":"Ann N Y Acad Sci"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2019.04.017","article-title":"Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study","volume":"205","author":"Hendricks TM","year":"2019","unstructured":"Hendricks TM, Bhatti MT, Hodge DO, Chen JJ. Incidence, epidemiology, and transformation of ocular myasthenia gravis: a population-based study. Am J Ophthalmol. 2019, 205:99-105. 10.1016\/j.ajo.2019.04.017","journal-title":"Am J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2014.904375","article-title":"The psychosocial impact of ptosis as a symptom of myasthenia gravis: a qualitative study","volume":"33","author":"Richards HS","year":"2014","unstructured":"Richards HS, Jenkinson E, Rumsey N, Harrad RA. The psychosocial impact of ptosis as a symptom of myasthenia gravis: a qualitative study. Orbit. 2014, 33:263-9. 10.3109\/01676830.2014.904375","journal-title":"Orbit"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.2840","article-title":"Prevalence of depression and anxiety among myasthenia gravis (MG) patients: a systematic review and meta-analysis","volume":"13","author":"Nadali J","year":"2023","unstructured":"Nadali J, Ghavampour N, Beiranvand F, et al.. Prevalence of depression and anxiety among myasthenia gravis (MG) patients: a systematic review and meta-analysis. Brain Behav. 2023, 13:e2840. 10.1002\/brb3.2840","journal-title":"Brain Behav"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000002790","article-title":"International consensus guidance for management of myasthenia gravis: executive summary","volume":"87","author":"Sanders DB","year":"2016","unstructured":"Sanders DB, Wolfe GI, Benatar M, et al.. International consensus guidance for management of myasthenia gravis: executive summary. Neurology. 2016, 87:419-25. 10.1212\/WNL.0000000000002790","journal-title":"Neurology"},{"key":"ref10","unstructured":"Oxymetazoline. (2023). https.\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Oxymetazoline."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/lary.27760","article-title":"Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children","volume":"129","author":"Cartabuke RS","year":"2019","unstructured":"Cartabuke RS, Anderson BJ, Elmaraghy C, Rice J, Tumin D, Tobias JD. Hemodynamic and pharmacokinetic analysis of oxymetazoline use during nasal surgery in children. Laryngoscope. 2019, 129:2775-81. 10.1002\/lary.27760","journal-title":"Laryngoscope"},{"key":"ref12","unstructured":"First blepharoptosis drug gains FDA approval. (2020). Accessed. July 14, 2020: https:\/\/www.aao.org\/education\/headline\/first-blepharoptosis-drug-gains-fda-approval."},{"key":"ref13","unstructured":"Flunisolide. (2024). Accessed. March 01, 2024:  https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Flunisolide."},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjps.2023.02.006","article-title":"The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: a randomized controlled trial","volume":"80","author":"Shoji MK","year":"2023","unstructured":"Shoji MK, Markatia Z, Ameli K, Bayaraa M, Clauss KD, Ugradar S, Lee WW. The effects of topical oxymetazoline on eyelid position, eye redness, and patient-reported eye appearance: a randomized controlled trial. J Plast Reconstr Aesthet Surg. 2023, 80:66-74. 10.1016\/j.bjps.2023.02.006","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2020.3812","article-title":"Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials","volume":"138","author":"Slonim CB","year":"2020","unstructured":"Slonim CB, Foster S, Jaros M, Kannarr SR, Korenfeld MS, Smyth-Medina R, Wirta DL. Association of oxymetazoline hydrochloride, 0.1%, solution administration with visual field in acquired ptosis: a pooled analysis of 2 randomized clinical trials. JAMA Ophthalmol. 2020, 138:1168-75. 10.1001\/jamaophthalmol.2020.3812","journal-title":"JAMA Ophthalmol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2009.03.015","article-title":"Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms","volume":"123","author":"Baroody FM","year":"2009","unstructured":"Baroody FM, Shenaq D, DeTineo M, Wang J, Naclerio RM. Fluticasone furoate nasal spray reduces the nasal-ocular reflex: a mechanism for the efficacy of topical steroids in controlling allergic eye symptoms. J Allergy Clin Immunol. 2009, 123:1342-8. 10.1016\/j.jaci.2009.03.015","journal-title":"J Allergy Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.4997\/JRCPE.2021.209","article-title":"Isolated oculomotor nerve palsy secondary to acute sinusitis","volume":"51","author":"Larcombe SJ","year":"2021","unstructured":"Larcombe SJ, Street D, Wright B. Isolated oculomotor nerve palsy secondary to acute sinusitis. J R Coll Physicians Edinb. 2021, 51:143-5. 10.4997\/JRCPE.2021.209","journal-title":"J R Coll Physicians Edinb"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-198019060-00001","article-title":"Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis","volume":"19","author":"Pakes GE","year":"1980","unstructured":"Pakes GE, Brogden RN, Heel RD, Speight TM, Avery GS. Flunisolide: a review of its pharmacological properties and therapeutic efficacy in rhinitis. Drugs. 1980, 19:397-411. 10.2165\/00003495-198019060-00001","journal-title":"Drugs"},{"key":"ref19","article-title":"Systemic side effects of locally used oxymetazoline","volume":"8","author":"Dokuyucu R","year":"2015","unstructured":"Dokuyucu R, Gokce H, Sahan M, et al.. Systemic side effects of locally used oxymetazoline. Int J Clin Exp Med. 2015, 8:2674-8.","journal-title":"Int J Clin Exp Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/237559-a-breath-of-relief-oxymetazoline-and-flunisolide-nasal-spray-in-the-management-of-myasthenia-gravis-ptosis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,23]],"date-time":"2024-04-23T11:30:01Z","timestamp":1713871801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/237559-a-breath-of-relief-oxymetazoline-and-flunisolide-nasal-spray-in-the-management-of-myasthenia-gravis-ptosis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,23]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.58812","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,23]]}}}